Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Cattrini

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
European Urology|March 8, 2020
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate CancerDavid Lorente, Elena Castro, Rebeca Lozano, et al.
Expert Review of Anticancer Therapy|April 5, 2023
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?Matilde Corianò, Diana Giannarelli, Giulia Scartabellati, et al.
Frontiers in Bioscience (Elite Edition)|September 24, 2023
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic ScoreGiulia Mazzaschi, Alessandro Lazzarin, Matteo Santoni, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 studyGiandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
Clinical Genitourinary Cancer|October 5, 2023
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective AnalysisChiara Pisano, Fabio Turco, Elena Arnaudo, et al.
Therapeutic Advances in Urology|October 28, 2021
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreakMelissa Bersanelli, Sebastiano Buti, Mimma Rizzo, et al.
Clinical Genitourinary Cancer|April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology|June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 StudyMatteo Santoni, Francesco Massari, Zin W Myint, et al.
European Urology Oncology|July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Minerva Urology and Nephrology|August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinationsCamillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
European Urology|March 8, 2020
Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate CancerDavid Lorente, Elena Castro, Rebeca Lozano, et al.
Expert Review of Anticancer Therapy|April 5, 2023
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?Matilde Corianò, Diana Giannarelli, Giulia Scartabellati, et al.
Frontiers in Bioscience (Elite Edition)|September 24, 2023
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic ScoreGiulia Mazzaschi, Alessandro Lazzarin, Matteo Santoni, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 studyGiandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
Clinical Genitourinary Cancer|October 5, 2023
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective AnalysisChiara Pisano, Fabio Turco, Elena Arnaudo, et al.
Therapeutic Advances in Urology|October 28, 2021
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreakMelissa Bersanelli, Sebastiano Buti, Mimma Rizzo, et al.
Clinical Genitourinary Cancer|April 16, 2023
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)Matteo Santoni, Francesco Massari, Zin W Myint, et al.
Targeted Oncology|June 27, 2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 StudyMatteo Santoni, Francesco Massari, Zin W Myint, et al.
European Urology Oncology|July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Minerva Urology and Nephrology|August 2, 2023
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinationsCamillo Porta, Aristotelis Bamias, Roubini Zakopoulou, et al.
Pageof 6